OGN
Organon & Co.
NYSE · Healthcare · Drug Manufacturers - General · US
$13.78
+0.04%Aug 1, 2026, 13:54 UTC
Sun Pharmaceutical Industries' proposed acquisition of Organon has been approved by shareholders.
Source:Jul 23, 2026, 15:07 UTC
Shareholders of Organon & Co. approved the merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting.
Source:Jul 4, 2026, 15:45 UTC
Sun Pharma announced it is buying American pharmaceutical company Organon in a deal valued at about $11.75 billion, including debt.
Source:Jul 1, 2026, 18:00 UTC
Organon & Co. reported quarterly earnings on April 30th, with EPS of $0.71 missing consensus of $0.83 and revenue of $1.46 billion missing consensus of $1.49 billion.
Source:Jul 1, 2026, 18:00 UTC
Organon & Co. shares hit a new 52-week high of $13.60 on Wednesday.
Jun 23, 2026, 09:30 UTC
Organon Canada and Shanghai Henlius Biotech launched BILDYOS and TUZEMTY, biosimilars to PROLIA and XGEVA, in Canada.
Source:Jun 22, 2026, 11:30 UTC
Organon completed a global licensing agreement with Sebela Pharmaceuticals to exclusively license MIUDELLA, a hormone-free copper IUD.
Source:Jun 18, 2026, 10:00 UTC
Organon and Samsung Bioepis expanded their agreement to commercialize PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA® (ustekinumab), in Canada.
Source:Jun 12, 2026, 14:16 UTC
Organon received FDA approval to expand the use of TOFIDENCE for severe cytokine release syndrome and certain hospitalized COVID-19 patients.
Source:Jun 10, 2026, 11:30 UTC
The US FDA approved Organon's supplemental Biologics License Application for TOFIDENCE (tocilizumab-bavi), expanding its indications to include cytokine release syndrome and pediatric COVID-19.
Source:Jun 2, 2026, 16:04 UTC
Brodsky & Smith is investigating potential breaches of fiduciary duty by Organon & Co.'s board in connection with the sale of Organon to Sun Pharmaceutical Industries Limited.
Source: